talapro-2: toxicities and treatment duration
Published 8 months ago • 31 plays • Length 6:54Download video MP4
Download video MP3
Similar videos
-
11:19
drs. fizazi, wallis on updated data from talapro-2
-
6:35
talazoparib plus enzalutamide: talapro-2 results and subset analyses
-
8:00
how has talapro-2 changed the standard of care for first-line mcrpc with hrr mutations?
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
5:03
which is better - surgery vs. radiation for prostate cancer?
-
8:25
radical prostatectomy for basic teal prostate cancer | prostate cancer staging guide
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:56
talapro-2: exposure efficacy of talazoparib and enzalutamide in mcrpc
-
5:21
talapro-2 phase iii study design
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
2:51
prostate cancer: treatment options and side effects
-
34:44
icaho19 - gu oncology session: management of prostate cancer
-
11:14
parp inhibitor combinations in first-line mcrpc: clinical trial shortcomings and increased toxicity
-
5:14
olaparib and keytruda for advanced prostate cancer | | learn about clinical trials
-
18:43
gu asco 2023 highlights - oncbrothers (rohit and rahul gosain) with dr. petros grivas
-
1:38
novel combination therapy regimen shows promising results for prostate cancer
-
38:47
uromigos live 2023: where do we stand with parp inhibitors in prostate cancer?